Peptide Vial Excipients: What’s Actually in the Vial

Formulation

Peptide vial excipients are everything in the vial that is not the peptide — the mannitol, sucrose, buffer salts, surfactant and, sometimes, the preservative. On an FDA-approved lyophilized peptide product they routinely outweigh the active peptide by more than ten to one, and each one is there to prevent a specific, well-documented failure.

If you have ever tipped a 2 mg peptide vial and wondered why there is so much powder in it, this is the answer. The powder is mostly not peptide. Understanding what the other ingredients do explains a surprising amount of downstream behaviour: why some products are freeze-dried and others are not, why some vials can be entered repeatedly and others cannot, and why the mass printed on a label is not always the mass of peptide you are working with.

What peptide vial excipients are, in regulatory terms

The term is regulatory before it is chemical. Under 21 CFR 210.3(b)(8), the FDA defines an inactive ingredient as any component of a drug product other than the active ingredient. The agency maintains a searchable Inactive Ingredient Database of every excipient that has appeared in an approved product, along with the maximum amount used per route of administration. Once an excipient has appeared in an approved product by a given route, it is no longer considered new, which is a large part of why the same short list of ingredients recurs across almost every injectable peptide.

One real vial, weighed out

EGRIFTA SV (tesamorelin) is a useful worked example because it is a lyophilized peptide in a single-dose vial, so its composition is public and complete. Each vial contains 2 mg of tesamorelin plus 0.78 mg histidine, 20 mg mannitol, 0.05 mg polysorbate 20 and 10 mg sucrose, with hydrochloric acid used to adjust pH, which falls between 4.5 and 7.4. Reconstituted with 0.5 mL of sterile water, it yields 2 mg per 0.5 mL.

That is 32.83 mg of powder for 2 mg of peptide — about fifteen parts excipient to one part active ingredient by mass.

Bulking agents and lyoprotectants: why there is sugar in the vial

Freeze-drying has three steps: freezing, primary drying (crystallised water is removed by sublimation under vacuum), and secondary drying (bound water is desorbed). Peptides and proteins are generally more stable in the dried, immobilised state because aggregation and hydrolysis both slow down — which is why so many peptides ship as a lyophilized powder in the first place. Primary drying is by far the most time-consuming step.

The catch is that the product temperature has to stay below the formulation's critical temperature or the cake collapses. Collapse temperature typically sits 1–3 °C above the glass transition temperature of the maximally freeze-concentrated solution, and for the disaccharides most commonly used as stabilisers — sucrose and trehalose — those temperatures are around −28 to −32 °C. That forces low shelf temperatures and long cycles.

Formulators therefore usually pair two things: a crystalline bulking agent such as mannitol, which gives the cake mechanical structure, and an amorphous stabiliser such as sucrose, which actually protects the molecule. The ratio is a genuine trade-off. Too little amorphous excipient and the peptide is poorly stabilised; too much mannitol and the formulation can crack the vial during freeze-drying. Every gram of excipient in that cake is buying either structure or stability.

Surfactants: the peptide that disappears into the glass

The strongest single argument for surfactant in a peptide formulation is a 2015 study that simply measured how much peptide survives contact with an ordinary container. Using analytical HPLC across borosilicate glass vials, polypropylene tubes, low-binding tubes and quartz cuvettes, the authors found that at typical working concentrations 90% or more of three cationic peptides was lost from solution by adsorption to the container walls. Adsorption was not confined to high surface-area-to-volume conditions.

The same physics operates at air–liquid and liquid–liquid interfaces. Peptides and proteins are amphiphilic, so they adsorb to interfaces and unfold there to reduce interfacial tension — which is a direct route to aggregation and particle formation. Non-ionic surfactants block this mainly by adsorbing to those interfaces preferentially themselves, sparing the peptide; secondary mechanisms include forming peptide–surfactant complexes and acting as a chemical chaperone.

Polysorbates 20 and 80 are the dominant family, used across roughly 0.003–3 mg/mL in protein drug products. Trulicity (dulaglutide), for instance, lists polysorbate 80 at 0.10–0.125 mg per single-dose pen alongside citrate buffer and mannitol, with no preservative at all. Polysorbates are not permanent, though: they autoxidise to hydroperoxides and hydrolyse at the fatty-acid ester bond, and their degradation products can themselves affect stability.

Buffers, pH and tonicity

Peptides have narrow pH windows in which deamidation, oxidation and hydrolysis are slowest, so the buffer is often the most consequential excipient in the vial. Real examples show how specific those windows are:

• Forteo (teriparatide) — glacial acetic acid and sodium acetate, with pH adjusted to 4, plus 45.4 mg/mL mannitol and 3 mg/mL metacresol; the label describes the solution as isotonic.
• Sandostatin (octreotide acetate) — lactic acid and sodium bicarbonate, and the label states outright that they “are added to provide a buffered solution, pH to 4.2 ± 0.3,” with 45 mg mannitol per ampoule.
• Ozempic (semaglutide) — disodium phosphate dihydrate 1.42 mg, propylene glycol 14 mg and phenol 5.5 mg per mL, at approximately pH 7.4.
• Humalog (insulin lispro) — dibasic sodium phosphate, glycerin 16 mg/mL, metacresol 3.15 mg/mL, trace phenol and zinc.

Note the spread: two peptides buffered near pH 4, two near neutrality. There is no universal “correct” pH for a peptide, only a correct one for that molecule's dominant degradation pathway.

Preservatives, and the single-dose versus multiple-dose rule

Whether a preservative is present has little to do with the peptide and almost everything to do with the container. The FDA defines a single-dose container as one that is not required to meet antimicrobial effectiveness testing requirements, and a multiple-dose container as one that has met them. Products meant to be entered repeatedly therefore generally need a preservative; single-dose vials, ampoules and pens do not. The agency also sets a default beyond-use date of 28 days for an opened multiple-dose container unless the manufacturer specifies otherwise, and notes such containers generally hold 30 mL or less. Insulin-style pens got their own term, “single-patient-use,” for exactly this reason.

Preservatives are not inert bystanders. An NMR study of a therapeutic peptide mapped m-cresol interactions to methionine, lysine, glutamate and glutamine residues through a mix of hydrophobic, hydrogen-bonding and electrostatic effects, and showed those site-specific interactions promoting higher-order oligomerisation that ended in insoluble aggregates. The Humalog label separately warns that localised reactions and generalised myalgias have been reported with injected metacresol. A preservative buys multi-dose convenience, and it charges for it.

Bacteriostatic water is itself an excipient decision

The diluent is part of the formulation. Bacteriostatic Water for Injection, USP is water for injection plus benzyl alcohol as a bacteriostatic preservative: 0.9% (9 mg/mL) in the 30 mL plastic multiple-dose vial and 1.1% (11 mg/mL) in the 20 mL glass vial, at pH 5.7 (range 4.5–7.0). It carries a boxed warning, NOT FOR USE IN NEONATES, and the label states it should not be used for fluid replacement or in epidural or spinal anaesthesia procedures. Sterile Water for Injection, USP by contrast “contains no bacteriostat, antimicrobial agent or added buffer” and is supplied only in single-dose containers. That is the whole of the bacteriostatic versus sterile water distinction, and it is also why the two have different post-opening timelines. Our bacteriostatic water guide covers the practical side.

Why a synthetic peptide powder can look almost empty

Material that is not an approved drug product carries no FDA-mandated ingredient list, so its composition cannot be assumed from the outside — that is a genuine limit on what anyone can say about it. What can be said is that “peptide only” is never literally true. Solid-phase synthesis uses trifluoroacetic acid as both a cleavage agent and an ion-pairing reagent, so synthesised peptides are typically isolated as TFA salts; converting that to a different counterion is a deliberate extra step, verified by techniques such as 19F-NMR and ion chromatography. Residual trifluoroacetate is not biologically silent either — it has been reported to inhibit proliferation of osteoblasts and chondrocytes. This is the same reason acetate and TFA salt forms are distinguished on a certificate of analysis, and it is bound up with net peptide content.

What this means for the arithmetic

Excipient mass is not peptide mass. A label that reads “10 mg” refers to the peptide, not to the weight of the cake, and the certificate of analysis is where the two are reconciled. Once the peptide quantity is established, the concentration relationships are straightforward arithmetic: our reconstitution calculator and concentration converter work out concentration in mg/mL and the corresponding volumes from a stated vial content and diluent volume.

Frequently asked questions

What is actually in bacteriostatic water?

Water for injection plus benzyl alcohol as a bacteriostatic preservative — 0.9% (9 mg/mL) in the 30 mL plastic vial and 1.1% (11 mg/mL) in the 20 mL glass vial, at pH 5.7. Sterile Water for Injection, USP contains no bacteriostat, antimicrobial agent or added buffer and is single-dose only.

Why is there sugar in a peptide vial?

Because a couple of milligrams of peptide cannot form a mechanically sound cake on its own, and because sugars stabilise the molecule in the dried state. EGRIFTA SV pairs 20 mg of crystalline mannitol for structure with 10 mg of amorphous sucrose for stabilisation. The ratio matters: too much mannitol has been reported to crack vials during freeze-drying.

Why do formulations contain polysorbate 20 or 80?

To stop the peptide adsorbing to surfaces and unfolding at interfaces. In one HPLC study, 90% or more of cationic peptide was lost from solution to ordinary glass and plastic container walls at typical working concentrations. Polysorbates adsorb to those interfaces preferentially, and are typically used at 0.003–3 mg/mL.

Why do some pens contain phenol or m-cresol when single-dose vials do not?

It is a packaging requirement. FDA defines single-dose containers as not required to meet antimicrobial effectiveness testing, while multiple-dose containers must meet it — so repeatedly entered products generally carry a preservative. Ozempic lists phenol at 5.5 mg/mL and Humalog lists metacresol at 3.15 mg/mL; preservative-free Trulicity pens, Sandostatin ampoules and EGRIFTA SV vials list none.

Informational only — not medical advice · 21+. VialHelp does not sell peptides and does not recommend any product or vendor. Consult a qualified healthcare professional for anything health-related.